FDA declines to approve Valeant's plaque psoriasis drug

June 18 (Reuters) - Valeant Pharmaceuticals International said on Monday that U.S. health regulators had declined to approve its drug to treat plaque psoriasis, citing questions related to certain data.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.